Mostrar el registro sencillo del ítem

dc.contributor.authorAguilar-Castillo, María José
dc.contributor.authorCabezudo-García, Pablo
dc.contributor.authorCiano-Petersen, Nicolas Lundahl
dc.contributor.authorGarcía-Martín, Guillermina
dc.contributor.authorMarín-Gracia, Marta
dc.contributor.authorEstivill-Torrús, Guillermo
dc.contributor.authorSerrano-Castro, Pedro Jesús 
dc.date.accessioned2022-05-31T09:01:11Z
dc.date.available2022-05-31T09:01:11Z
dc.date.issued2022-03-19
dc.identifier.citationAguilar-Castillo MJ, Cabezudo-García P, Ciano-Petersen NL, García-Martin G, Marín-Gracia M, Estivill-Torrús G, Serrano-Castro PJ. Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies. Biomedicines. 2022; 10(3):716. https://doi.org/10.3390/biomedicines10030716es_ES
dc.identifier.urihttps://hdl.handle.net/10630/24251
dc.description.abstractImmunologic and neuroinflammatory pathways have been found to play a major role in the pathogenesis of many neurological disorders such as epilepsy, proposing the use of novel therapeutic strategies. In the era of personalized medicine and in the face of the exhaustion of anti-seizure therapeutic resources, it is worth looking at the current or future possibilities that neuroimmunomodulator or anti-inflammatory therapy can offer us in the management of patients with epilepsy. For this reason, we performed a narrative review on the recent advances on the basic epileptogenic mechanisms related to the activation of immunity or neuroinflammation with special attention to current and future opportunities for novel treatments in epilepsy. Neuroinflammation can be considered a universal phenomenon and occurs in structural, infectious, post-traumatic, autoimmune, or even genetically based epilepsies. The emerging research developed in recent years has allowed us to identify the main molecular pathways involved in these processes. These molecular pathways could constitute future therapeutic targets for epilepsy. Different drugs current or in development have demonstrated their capacity to inhibit or modulate molecular pathways involved in the immunologic or neuroinflammatory mechanisms described in epilepsy. Some of them should be tested in the future as possible antiepileptic druges_ES
dc.description.sponsorshipThis research was funded by Andalusian Network of Clinical and Translational Research in Neurology (Neuro-RECA) of the Consejería de Salud y Familias de la Junta de Andalucía (Code: RIC-0111-2019). Partial funding for open access charge: Universidad de Málagaes_ES
dc.language.isoenges_ES
dc.publisherIOAP-MPDIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEpilepsiaes_ES
dc.subject.otherEpilepsyes_ES
dc.subject.otherNeuroinflammationes_ES
dc.subject.otherNeuroimmunologyes_ES
dc.subject.otherTreatmentes_ES
dc.subject.otherEpileptogenesises_ES
dc.titleImmune Mechanism of Epileptogenesis and Related Therapeutic Strategieses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.centroFacultad de Medicinaes_ES
dc.identifier.doihttps://doi.org/10.3390/biomedicines10030716
dc.rights.ccAtribución 4.0 Internacional*


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional